Literature DB >> 9316827

Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor.

D Ghanekar1, E M Hadac, E L Holicky, L J Miller.   

Abstract

The mouse cholecystokinin (CCK) receptor is functionally distinct from the extensively studied rat receptor on the basis of differences in binding and biological activity of phenethyl ester analogs of CCK. These are partial agonists at the rat receptor and full agonists at the mouse pancreatic receptor. To explore this, we cloned the cDNA for the mouse type A CCK receptor, established a receptor-bearing Chinese hamster ovary (CHO) cell line and characterized its binding and biological characteristics. Despite 25 differences in amino acid sequence from the rat receptor, including a seven-amino acid insertion in the third intracellular loop, mouse and rat receptors were functionally indistinguishable when expressed in CHO cells. Of note, in the mouse pancreatic cell environment, a stable analog of guanosine triphosphate significantly inhibited binding of CCK-OPE, whereas it had no effect on binding to the same receptor on the CHO-CCKM cell line or to the rat receptor in either environment of the acinar cell. This likely reflects a difference in coupling of the mouse receptor to its G protein in the natural environment of the acinar cell. This may relate to differences extrinsic to the receptor, in the stoichiometry or character of G proteins or in the composition or organization of the lipid environment of the mouse acinar cell membrane. Although this may require complementation of the unique sequence of the mouse receptor, that structure alone is insufficient to explain this phenomenon. Receptor microenvironment makes an important, yet often ignored, contribution to receptor function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316827

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Molecular cloning, expression and pharmacological characterization of the canine cholecystokinin 1 receptor.

Authors:  Magda Francesca Morton; Jayashree Pyati; Heng Dai; Lina Li; Veronica Moreno; Nigel Paul Shankley
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

2.  Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor.

Authors:  Géraldine Ibarz; Catherine Oiry; Eric Carnazzi; Philippe Crespy; Chantal Escrieut; Daniel Fourmy; Jean Claude Galleyrand; Didier Gagne; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

3.  Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells.

Authors:  Toshiki Tanaka; Takeaki Yano; Tetsuya Adachi; Taka-aki Koshimizu; Akira Hirasawa; Gozoh Tsujimoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-03-05       Impact factor: 3.000

4.  Comparative pharmacology of cholecystokinin induced activation of cultured vagal afferent neurons from rats and mice.

Authors:  Dallas C Kinch; James H Peters; Steven M Simasko
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

5.  Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.

Authors:  Kaleeckal G Harikumar; Thomas Coudrat; Aditya J Desai; Maoqing Dong; Daniela G Dengler; Sebastian G B Furness; Arthur Christopoulos; Denise Wootten; Eduard A Sergienko; Patrick M Sexton; Laurence J Miller
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-07       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.